Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 97 positions · Total reported value $2.81B · Top-10 concentration 53.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Soleus Capital Management, L.P. disclosed 97 equity positions with a combined reported value of $2.81B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were KRYS ($379.02M), PODD ($225.26M), NVCR ($150.34M). By sector, the heaviest allocations are Health Care 98.6%, Technology 0.0%.

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q3 2026 were ZLAB ($40.64M), KOD ($27.20M), INBX ($21.02M).

Of the 27 positions fully exited versus the prior quarter, the largest were GMED ($37.05M), SUPN ($24.19M), LIVN ($20.97M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ZLAB ZAI LAB LTD · $40.64M
  • KOD KODIAK SCIENCES INC · $27.20M
  • INBX INHIBRX BIOSCIENCES INC · $21.02M
  • CNMD CONMED CORP · $16.06M
  • ETON ETON PHARMACEUTICALS INC · $15.86M
  • GRAL GRAIL INC · $15.20M
  • AMRX AMNEAL PHARMACEUTICALS INC · $13.25M
  • SNY SANOFI SA · $11.34M

Fully Exited (vs previous quarter)

  • GMED GLOBUS MED INC · prev qtr: $37.05M
  • SUPN SUPERNUS PHARMACEUTICALS · prev qtr: $24.19M
  • LIVN LIVANOVA PLC · prev qtr: $20.97M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $13.05M
  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $9.95M
  • IMVT IMMUNOVANT INC · prev qtr: $9.71M
  • NKTR NEKTAR THERAPEUTICS · prev qtr: $8.96M
  • MIRM MIRUM PHARMACEUTICALS INC · prev qtr: $8.78M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare names (e.g., KRYS, PODD, UTHR, ERAS) while trimming others (e.g., NVCR, TGTX, CELC), suggesting a bullish but selective stance on healthcare innovation, particularly in gene therapy and diabetes management. 2. Key moves: - Added: KRYS (+21.3% shares), PODD (+64.6% shares), UTHR (+14.8% shares), ERAS (+89.3% shares). - Reduced: NVCR (-4.9% shares), TGTX (-12.7% shares), CELC (-1.3% shares), INSP (-37.5% shares), BBNX (-14.8% shares). 3. Portfolio structure: Active, concentrated (97 positions), heavily biased toward Health Care (100% of top 10), with high risk appetite (volatile biotech names, significant share swings). 4. Per-holding one-liner: - KRYS: Krystal Biotech (gene therapy) - PODD: Insulet (insulin pumps) - NVCR: Novocure (tumor treatment fields) - TGTX: TG Therapeutics (B-cell malignancies) - UTHR: United Therapeutics (pulmonary hypertension) - CELC: Celcuity (cancer diagnostics) - RIGL: Rigel Pharmaceuticals (autoimmune/inflammatory) - INSP: Inspire Med Systems (sleep apnea) - ERAS: Erasca (cancer therapeutics) - BBNX: Beta Bionics (artificial pancreas) 5. Style summary: Aggressive biotech focus with tactical bets on high-growth therapeutics and devices, trimming laggards.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:03

Sector Allocation

Health Care 98.6%
Technology 0.0%
Other 1.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.14M $379.02M 13.47%
13.47%
Add
2 1.73M $225.26M 8.01%
8.01%
Add
3 9.43M $150.34M 5.34%
5.34%
Reduce
4 2.56M $142.58M 5.07%
5.07%
Reduce
5 259.00K $140.35M 4.99%
4.99%
Add
6 1.68M $133.81M 4.76%
4.76%
Reduce
7 1.84M $88.76M 3.15%
3.15%
Hold
8 1.21M $83.71M 2.98%
2.98%
Reduce
9 5.11M $74.94M 2.66%
2.66%
Add
10 3.74M $71.06M 2.53%
2.53%
Reduce
11 975.50K $70.87M 2.52%
2.52%
Add
12 1.55M $62.38M 2.22%
2.22%
Add
13 46.77M $57.53M 2.04%
2.04%
Add
14 1.68M $54.39M 1.93%
1.93%
Add
15 49.35K $47.32M 1.68%
1.68%
Add
16 1.08M $45.32M 1.61%
1.61%
Add
17 3.22M $44.28M 1.57%
1.57%
Add
18 5.09M $40.72M 1.45%
1.45%
Add
19 1.54M $40.64M 1.45%
1.45%
New
20 1.58M $39.85M 1.42%
1.42%
Reduce
21 2.73M $39.06M 1.39%
1.39%
Add
22 1.71M $36.13M 1.28%
1.28%
Add
23 7.31M $32.67M 1.16%
1.16%
Hold
24 1.02M $29.03M 1.03%
1.03%
Add
25 286.97K $27.20M 0.97%
0.97%
New
26 2.39M $26.08M 0.93%
0.93%
Add
27 11.22M $23.07M 0.82%
0.82%
Add
28 862.00K $22.27M 0.79%
0.79%
Reduce
29 1.09M $21.59M 0.77%
0.77%
Reduce
30 892.16K $21.15M 0.75%
0.75%
Reduce
31 210.00K $21.02M 0.75%
0.75%
New
32 1.27M $20.36M 0.72%
0.72%
Add
33 15.00M $20.24M 0.72%
0.72%
Add
34 497.71K $20.17M 0.72%
0.72%
Reduce
35 802.30K $20.02M 0.71%
0.71%
Add
36 667.84K $19.92M 0.71%
0.71%
Add
37 604.00K $19.16M 0.68%
0.68%
Reduce
38 147.00K $16.78M 0.60%
0.60%
Add
39 56.52K $16.46M 0.58%
0.58%
Reduce
40 1.17M $16.45M 0.58%
0.58%
Reduce
41 218.96K $16.34M 0.58%
0.58%
Reduce
42 347.33K $16.06M 0.57%
0.57%
New
43 308.10K $15.86M 0.56%
0.56%
New
44 710.20K $15.82M 0.56%
0.56%
Reduce
45 11.30M $15.48M 0.55%
0.55%
Add
46 108.50K $15.20M 0.54%
0.54%
New
47 258.90K $15.18M 0.54%
0.54%
Reduce
48 329.99K $13.40M 0.48%
0.48%
Reduce
49 658.00K $13.25M 0.47%
0.47%
New
50 3.38M $13.21M 0.47%
0.47%
Hold

FAQ

What did Soleus Capital Management, L.P. buy in 2026-Q3?

In its 2026-Q3 13F filing, Soleus Capital Management, L.P. reported 97 equity positions worth $2.81B in aggregate; its largest disclosed positions were KRYS ($379.02M), PODD ($225.26M), NVCR ($150.34M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $2.81B of long equity holdings across 97 positions as of 2026-Q3. Top-10 holdings account for 53.0% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →